Validation experiment designed to validate causal mechanisms targeting NTN1 in A549 human cancer cell xenografts in mice. Primary outcome: EMT reduction in transplanted A549 cells
This experiment tested the therapeutic efficacy of NP137 in a human cancer xenograft model using A549 cells. The A549 human cancer cell line, which undergoes EMT following TGFβ1 administration, was transplanted into mice. The transplanted mice were then treated with NP137 to assess whether netrin-1 inhibition could decrease EMT in human cancer cells in vivo. Results demonstrated that netrin-1 inhibition successfully decreased EMT in the transplanted A549 cells, validating the relevance of netrin-1 targeting for human cancer treatment and supporting the translational potential of this therapeutic approach.
Transplantation of A549 cells into mice, TGFβ1-induced EMT, followed by NP137 treatment and EMT assessment
Decreased EMT in A549 cells following NP137 treatment
Significant reduction in EMT markers in transplanted human cancer cells
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.